Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently transforming acute myeloid leukemia (AML) therapy. However, there is a lack of clinically relevant biomarkers that predict response to 5-AZA/VEN. Here, we integrated transcriptomic, proteomic, functional, and cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Waclawiczek, Alexander, Leppä, Aino-Maija, Renders, Simon, Stumpf, Karolin, Reyneri, Cecilia, Betz, Barbara, Janssen, Maike, Shahswar, Rabia, Donato, Elisa, Karpova, Darja, Thiel, Vera, Unglaub, Julia M., Grabowski, Susanna, Gryzik, Stefanie, Vierbaum, Lisa, Schlenk, Richard F., Röllig, Christoph, Hundemer, Michael, Pabst, Caroline, Heuser, Michael, Raffel, Simon, Müller-Tidow, Carsten, Sauer, Tim, Trumpp, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236156/
https://www.ncbi.nlm.nih.gov/pubmed/36892565
http://dx.doi.org/10.1158/2159-8290.CD-22-0939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236156/
https://www.ncbi.nlm.nih.gov/pubmed/36892565
http://dx.doi.org/10.1158/2159-8290.CD-22-0939

Ejemplares similares